Balcells: Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial

Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial

Balcells et al., PLOS Medicine, doi:10.1371/journal.pmed.1003415

Balcells et al., Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized.., PLOS Medicine, doi:10.1371/journal.pmed.1003415

Mar 2021 Source PDF

Twitter
Facebook

All Studies Meta

Small RCT with 28 early and 30 deferred (treated according to prespecified deterioration criteria) convalescent plasma patients, not showing significant differences. "Early" is relative, with a median of 5 days from symptom onset. 13 patients in the deferred group received plasma.

Important missing comments or errors? Let us know.

risk of death, 247.4% higher, RR 3.47, p = 0.17, treatment 5 of 28 (17.9%), control 2 of 30 (6.7%), adjusted per study, odds ratio converted to relative risk, logistic regression, early vs. deferred.

risk of mechanical ventilation, 163.3% higher, RR 2.63, p = 0.22, treatment 5 of 28 (17.9%), control 2 of 30 (6.7%), adjusted per study, odds ratio converted to relative risk, logistic regression, early vs. deferred.

risk of progression, 23.3% higher, RR 1.23, p = 0.51, treatment 13 of 28 (46.4%), control 12 of 30 (40.0%), adjusted per study, odds ratio converted to relative risk, logistic regression, early vs. deferred.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Balcells et al., 3 Mar 2021, Randomized Controlled Trial, Chile, peer-reviewed, 32 authors, average treatment delay 5.0 days.

All Studies All Outcomes Submit Updates or Corrections

This Paper Conv. Plasma All

Abstract: RESEARCH ARTICLE Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 OPEN ACCESS Citation: Balcells ME, Rojas L, Le Corre N, Martı́nez-Valdebenito C, Ceballos ME, Ferrés M, et al. (2021) Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial. PLoS Med 18(3): e1003415. https://doi.org/ 10.1371/journal.pmed.1003415 Academic Editor: Sanjay Basu, Harvard Medical School, UNITED STATES Marı́a Elvira Balcells ID1☯*, Luis Rojas ID2,3☯, Nicole Le Corre ID4,5, Constanza Martı́nezValdebenito ID4,5, Marı́a Elena Ceballos ID1, Marcela Ferrés4,5, Mayling Chang6, Cecilia Vizcaya4, Sebastián Mondaca6, Álvaro Huete ID7, Ricardo Castro ID8, Mauricio Sarmiento ID6, Luis Villarroel ID9, Alejandra Pizarro1, Patricio Ross ID2, Jaime Santander ID10, Bárbara Lara ID11, Marcela Ferrada12, Sergio Vargas-Salas ID6, Carolina Beltrán-Pavez13,14, Ricardo Soto-Rifo ID13,14, Fernando Valiente-Echeverrı́a13,14, Christian Caglevic15, Mauricio Mahave15, Carolina Selman15, Raimundo Gazitúa ID15, José Luis Briones ID15, Franz Villarroel-Espindola15,16, Carlos Balmaceda17, Manuel A. Espinoza ID9, Jaime Pereira6, Bruno Nervi6 1 Department of Infectious Diseases, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile, 2 Department of Internal Medicine, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile, 3 Program of Pharmacology and Toxicology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile, 4 Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile, 5 Diagnostic Virology Laboratory, Red de Salud UC CHRISTUS, Santiago, Chile, 6 Department of Hematology and Oncology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile, 7 Department of Radiology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile, 8 Department of Intensive Care Medicine, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile, 9 Department of Public Health, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile, 10 Department of Psychiatry, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile, 11 Emergency Medicine Section, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile, 12 Clinical Research Center, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile, 13 Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile, 14 HIV/AIDS Work Group, Faculty of Medicine, Universidad de Chile, Santiago, Chile, 15 Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile, 16 Translational Medicine Research Laboratory, Fundación Arturo López Pérez, Santiago, Chile, 17 Health Technology Assessment Unit, Clinical Research Center, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile Received: September 18, 2020 Accepted: January 12, 2021 ☯ These authors contributed equally to this work. * ebalcells@uc.cl Published: March 3, 2021 Peer Review History: PLOS recognizes the benefits of transparency in the peer review process;..

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit